Navigation Links
Exciting new avenues of research and policy drive expansion of HIV treatment access, use of antiretrovirals to prevent infections and pursuit of a cure
Date:7/21/2010

21 July 2010 [Vienna, Austria]The unwillingness of the global AIDS community to accept the status quo is fuelling a new era of scientific innovation to drive novel ways of treating and preventing HIV, organizers of the XVIII International AIDS Conference (AIDS 2010) taking place in Vienna, Austria said today. And, with millions of lives dependent on expanding access to antiretroviral treatment to all those clinically in need, researchers and clinicians are partnering in new ways to find the most effective and efficient methods to deliver treatment and strengthen health systems. A new Medicines Patent Pool described in today's plenary session also offers the possibility of broader access to more effective and less toxic regimens.

"The inspiring element of the conference so far has been the marriage of cutting edge science and innovative policy and programming," said Dr. Brigitte Schmied, AIDS 2010 Local Co-Chair and President of the Austrian AIDS Society. "We need that same energy and creativity to break through the HIV-related stigma and discrimination that prevents too many from benefitting from the knowledge we already have about how to save lives."

Growing evidence of the power of antiretroviral drugs to prevent new infections offers the possibility of a major step toward universal access to HIV prevention while increasing access to lifesaving care. The use of treatment science to develop new prevention modalities, such as the antiretroviral-based vaginal microbicide used in the CAPRISA trial, whose results were released this week, is a further example of the drive to provide a variety of effective new prevention options.

"Additional evidence demonstrating the potential use of antiretroviral drugs to prevent infections coupled with other exciting scientific advances discussed this week signal a potential new era in innovation," said Dr. Julio Montaner, AIDS 2010 Chair, President of the International AIDS Society and Director of the B.C. Centre for Excellence in HIV/AIDS in Vancouver, Canada. "At the same time, with lifesaving treatment and prevention tools readily available now, world leaders must step up and fund universal access."

There is also an increasing focus on the development and pursuit of strategies for a cure. Key experts in the area of latent viral reservoirs met just prior to the conference to examine new scientific results in this arena to inform the way forward. The meeting was also convened to encourage young investigators to work on this priority topic. Participants will provide an update in a press conference at 14:00 today.

Wednesday's plenary session included three provocative presentations:

Anti-HIV Drugs for Prevention

Dr. Bernard Hirschel (Switzerland) of the Infectious Diseases Service Geneva University Hospitals said that treatment as prevention is a promising strategy that needs to be properly evaluated in clinical trials. It is known that decreased viral load lowers the risk of HIV transmission and that effective treatment lowers viral load to undetectable levels. Therefore, if one could identify and treat all PLHIV, the AIDS epidemic would wither and die away. However, such a radical solution is a "pipe dream". In reality, the preventive potential of ART currently is not fully characterized. Modelers have tried to fill the gap, but models differ depending on assumptions, which are debated. As treatment expands, incidence in some cities has fallen, which is encouraging, but correlation does not necessarily imply causation. Studies in sero-discordant couples appear to show that treatment protects from transmission, as well, but such couples are only part of the sexually active population potentially at risk.

Funding agencies are currently evaluating proposals for more definitive studies, where a number of communities are randomized to receive the "test-and-treat" approach, or continue as before. These trials face logistical, practical and ethical obstacles. However, without more definitive data, the intuitive appeal of "test-and-treat" is unlikely to translate into action on a global scale. In the meantime, based on the available evidence, the medical community must strive to provide treatment under current guidelines to those patients in need, leading to better individual and societal outcomes, including decreasing HIV incidence.

A Proposal for Change: Managing Patents for Access to AIDS Medicines for All

Ellen 't Hoen (The Netherlands) of UNITAID discussed the Medicines Patent Pool, a new mechanism that allows patent holders to voluntarily offer the intellectual property related to their AIDS medicines, under certain conditions. Any company wishing to use the intellectual property to produce the drugs can do so in exchange for a royalty payment. t'Hoen noted that if licenses for patents on AIDS drugs are not made available in countries that grant patents, generic competition will no longer be able to play a role in bringing down prices.

Over the past 10 years, activism, generic competition for medications, the development of fixed-dose combinations, and many countries' willingness to use flexibilities in national and international patent rules have greatly increased access to antiretroviral therapy, according to t'Hoen. However, many patients will soon need to switch to much more expensive second- and third-line drugs and the World Health Organization (WHO) is recommending newer, safer, patent-protected medications. By making licenses available and harnessing the power of competition in medicines markets, the Medicines Patent Pool could promote the availability of better and more robust treatments and generate considerable cost savings.

ART Advances Into the Next Decade

Dr. James Hakim (Zimbabwe) of the University of Zimbabwe called on the HIV/AIDS community to accelerate access to antiretroviral therapy that maintains the long-term health of PLHIV; develop point-of-care diagnostics that allow clinicians to prescribe medications wisely; and improve health delivery systems that can efficiently provide therapy to those still in need. He said that despite the rapid scale-up of ART, the world is not moving fast enough to keep up with the pace of five new HIV infections for every two PLHIV who gain access to ART.

New WHO treatment guidelines recommend phasing out older, more toxic drugs and beginning therapy at higher CD4 counts, which increases the number of PLHIV eligible for treatment. As countries move to adopt these recommendations, equity and human rights must remain paramount to implementing a progressive and comprehensive HIV response. He concluded that the

Millennium Development Goals serve as a clear roadmap to the overall achievement of the sanctity of human dignity.


'/>"/>

Contact: Regina Aragon
Regina.Aragon@gmail.com
43-699-172-85713
International AIDS Society
Source:Eurekalert

Related biology news :

1. Exciting new companies at NJITs small biz incubator get 100K in lrants
2. Exciting new companies at NJITs small biz incubator get 100K in grants
3. Engineers: Weak laser can ignite nanoparticles, with exciting possibilities
4. Genes from tiny marine algae suggest unsuspected avenues for new research
5. Parasitic wasps newly sequenced genomes reveal new avenues for pest control
6. Wistar Institute researcher receives New Innovator award from NIH
7. NC State researchers get to root of parasite genome
8. White Mountain Research Station to host climate change conference
9. Stevens awarded $1M for advanced biofuels research
10. Researchers find animal with ability to survive climate change
11. Researchers find an essential gene for forming ears of corn
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... 31, 2016  Genomics firm Nabsys has completed a ... Barrett Bready , M.D., who returned to the company ... technical leadership team, including Chief Technology Officer, John ... Steve Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys ...
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
(Date:3/22/2016)... , PROVO and ... -- Newborn Screening Ontario (NSO), which operates the highest ... for molecular testing, and Tute Genomics and UNIConnect, leaders ... technology respectively, today announced the launch of a project ... sequencing (NGS) testing panel. NSO has ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
Breaking Biology Technology: